$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc

$imuc Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000162828016019182 Filed on August 22, 2016

Income Statement

Concept	2016 Q3	2016 Q2	2015 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$910.0K	$1.050M	$1.150M
YoY Change	-20.87%	-8.7%	18.56%
% of Gross Profit
Research & Development	$4.564M	$4.433M	$2.300M
YoY Change	71.42%	92.76%	57.53%
% of Gross Profit
Depreciation & Amortization	$17.26K	$20.59K	$6.592K
YoY Change	146.62%	212.39%	-41.58%
% of Gross Profit
Operating Expenses	$5.472M	$5.483M	$3.388M
YoY Change	46.09%	61.86%	39.59%
Operating Profit	-$5.472M	-$5.483M	-$3.388M
YoY Change	46.09%	61.86%	39.59%
Interest Expense	$342.3K	$282.0K	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$4.798M	-$5.330M	-$3.155M
YoY Change	41.06%	68.94%	43.45%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.798M	-$5.330M	-$3.155M
YoY Change	41.06%	68.94%	43.45%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.584M	-$2.297M	-$1.394M
COMMON SHARES
Basic Shares Outstanding	127.9M shares	93.22M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q3	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.30M	$11.95M	$30.91M
YoY Change	-37.4%	-61.34%	20.46%
Cash & Equivalents	$15.30M	$11.95M	$30.91M
Short-Term Investments
Other Short-Term Assets	$631.2K	$767.0K	$1.300M
YoY Change	-52.54%	-41.0%	34.02%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$16.97M	$14.38M	$32.21M
YoY Change	-34.15%	-55.36%	20.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$126.7K	$144.0K	$40.00K
YoY Change	-36.64%	259.94%	-20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.140M	$4.740M	$900.0K
YoY Change	5.11%	426.67%	95.65%
Total Long-Term Assets	$5.262M	$4.889M	$950.0K
YoY Change	3.47%	414.61%	86.27%
TOTAL ASSETS
Total Short-Term Assets	$16.97M	$14.38M	$32.21M
Total Long-Term Assets	$5.262M	$4.889M	$950.0K
Total Assets	$22.23M	$19.27M	$33.16M
YoY Change	-27.95%	-41.9%	22.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$471.6K	$709.2K	$450.0K
YoY Change	-45.16%	57.59%	-27.42%
Accrued Expenses	$902.6K	$601.7K	$370.0K
YoY Change	-21.52%	62.61%	-26.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.733M	$1.642M	$820.0K
YoY Change	-13.33%	100.21%	-26.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$8.860M	$5.740M	$2.890M
YoY Change	246.09%	98.62%	129.37%
Total Long-Term Liabilities	$8.860M	$5.740M	$2.890M
YoY Change	246.09%	98.62%	129.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.733M	$1.642M	$820.0K
Total Long-Term Liabilities	$8.860M	$5.740M	$2.890M
Total Liabilities	$10.60M	$7.386M	$3.720M
YoY Change	132.4%	98.54%	56.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$89.90M	-$85.10M
YoY Change
Common Stock	$101.5M	$96.98M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.63M	$11.88M	$29.44M
YoY Change
Total Liabilities & Shareholders Equity	$22.23M	$19.27M	$33.16M
YoY Change	-27.95%	-41.9%	22.18%

Cashflow Statement

Concept	2016 Q3	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$4.798M	-$5.330M	-$3.155M
YoY Change	41.06%	68.94%	43.45%
Depreciation, Depletion And Amortization	$17.26K	$20.59K	$6.592K
YoY Change	146.62%	212.39%	-41.58%
Cash From Operating Activities	-$4.930M	-$5.840M	-$3.860M
YoY Change	-21.87%	51.3%	42.44%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$10.00K
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$10.00K
YoY Change	-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.280M	280.0K	0.000
YoY Change	82700.0%		-100.0%
NET CHANGE
Cash From Operating Activities	-4.930M	-5.840M	-3.860M
Cash From Investing Activities	0.000	0.000	-10.00K
Cash From Financing Activities	8.280M	280.0K	0.000
Net Change In Cash	3.350M	-5.560M	-3.870M
YoY Change	-151.86%	43.67%	-724.19%
FREE CASH FLOW
Cash From Operating Activities	-$4.930M	-$5.840M	-$3.860M
Capital Expenditures	$0.00	$0.00	-$10.00K
Free Cash Flow	-$4.930M	-$5.840M	-$3.850M
YoY Change	-19.84%	51.69%	42.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000822411
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	127945802	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	ImmunoCellular Therapeutics, Ltd.
	dei	Trading Symbol TradingSymbol	IMUC
	imuc	Change In Fair Value Of Warrant Liability For Income Taxes ChangeInFairValueOfWarrantLiabilityForIncomeTaxes	0.17
	imuc	Change In Fair Value Of Warrant Liability For Income Taxes ChangeInFairValueOfWarrantLiabilityForIncomeTaxes	0.04
CY2015Q2	imuc	Charge To Financing Expense ChargeToFinancingExpense	0	USD
	imuc	Charge To Financing Expense ChargeToFinancingExpense	88939	USD
CY2016Q2	imuc	Charge To Financing Expense ChargeToFinancingExpense	16595	USD
	imuc	Charge To Financing Expense ChargeToFinancingExpense	31231	USD
CY2015Q1	imuc	Common Stock And Warrants Issued For Cash Per Share CommonStockAndWarrantsIssuedForCashPerShare	0.60
CY2015Q1	imuc	Common Stock Of Public Offering CommonStockOfPublicOffering	3666836	shares
CY2014Q4	imuc	Common Stock Shares Purchased Private Placement Warrant CommonStockSharesPurchasedPrivatePlacementWarrant	2949867	shares
CY2012Q4	imuc	Common Stock Shares Purchased Private Placement Warrant CommonStockSharesPurchasedPrivatePlacementWarrant	2823670	shares
CY2016Q1	imuc	Common Stock Shares Purchased Private Placement Warrant CommonStockSharesPurchasedPrivatePlacementWarrant	3666836	shares
CY2016Q1	imuc	Common Stock Value Authorizedto Issue CommonStockValueAuthorizedtoIssue	15081494	USD
CY2016Q2	imuc	Common Stock Value Availablefor Sale Under Agreement CommonStockValueAvailableforSaleUnderAgreement	14300000	USD
	imuc	Initial Valuation Of Warrants InitialValuationOfWarrants	2476790	USD
	imuc	Issuance Of Warrants And Effect Of Repricing IssuanceOfWarrantsAndEffectOfRepricing	4286314	USD
	imuc	Issuance Of Warrants And Effect Of Repricing IssuanceOfWarrantsAndEffectOfRepricing	31231	USD
	imuc	Minimum Percentage Of Fair Market Value Of Common Stock MinimumPercentageOfFairMarketValueOfCommonStock	less than 110%
	imuc	Minimum Percentageof Fair Market Valueof Common Stock Percent MinimumPercentageofFairMarketValueofCommonStockPercent	1.1
	imuc	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	0	USD
	imuc	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	79440	USD
	imuc	Percentage Of Annual Increase Of Monthly Base Rent PercentageOfAnnualIncreaseOfMonthlyBaseRent	0.03
	imuc	Percentage Of Common Stock Voting Rights Held PercentageOfCommonStockVotingRightsHeld	more than 10%
	imuc	Percentage Of Fair Market Value Of Common Stock PercentageOfFairMarketValueOfCommonStock	not be less than 100%
	imuc	Percentageof Common Stock Voting Rights Held Percent PercentageofCommonStockVotingRightsHeldPercent	0.1
	imuc	Percentageof Fair Market Valueof Common Stock Percent PercentageofFairMarketValueofCommonStockPercent	1
	imuc	Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering	14599627	USD
	imuc	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate	0
	imuc	Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering	0	USD
CY2013Q2	imuc	Rate Of Commission RateOfCommission	0.030
	imuc	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate	0
CY2015Q1	imuc	Stock Issued During Period Shares Private Placement StockIssuedDuringPeriodSharesPrivatePlacement	26650000	shares
CY2016Q1	imuc	Stock Offering Maximum Public Float StockOfferingMaximumPublicFloat	75000000	USD
	imuc	Warrant Liability Gain Loss Included In Earnings WarrantLiabilityGainLossIncludedInEarnings	1989162	USD
	imuc	Warrant Liability Gain Loss Included In Earnings WarrantLiabilityGainLossIncludedInEarnings	926671	USD
CY2010Q2	imuc	Warrants Exercisable Period After Initial Issuance WarrantsExercisablePeriodAfterInitialIssuance	P5Y
CY2011Q1	imuc	Warrants Exercisable Period After Initial Issuance WarrantsExercisablePeriodAfterInitialIssuance	P5Y
CY2012Q1	imuc	Warrants Exercisable Period After Initial Issuance WarrantsExercisablePeriodAfterInitialIssuance	P5Y
	imuc	Warrants Exercised WarrantsExercised	0	USD
	imuc	Warrants Exercised WarrantsExercised	0	USD
	imuc	Warrants Liability Transfers Net WarrantsLiabilityTransfersNet	0	USD
	imuc	Warrants Liability Transfers Net WarrantsLiabilityTransfersNet	0	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1161258	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	709167	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	317653	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	601658	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	191089	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	232052	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	95849005	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	96971853	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	480947	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	-48977	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	39032089	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	37120034	shares
CY2015Q4	us-gaap	Assets Assets	30082374	USD
CY2016Q2	us-gaap	Assets Assets	19266350	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	24560538	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	14377536	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23222296	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30907953	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22604481	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11948858	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7685657	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10655623	USD
CY2015Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	21818229	USD
CY2016Q2	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	7967861	USD
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.79
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.64
CY2012Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.87
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.44
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10000000	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	249000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	249000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90310149	shares
CY2015Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	4176280	USD
	us-gaap	Depreciation Depreciation	40963	USD
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	93395802	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90310149	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93395802	shares
CY2016Q2	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	111165945	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	9031	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	9340	USD
CY2015Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	48977	USD
CY2016Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	228103	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16302000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23625396	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2191000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2791687	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18493000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26417083	USD
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2016Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	3449006	USD
CY2015Q2	us-gaap	Depreciation Depreciation	6592	USD
	us-gaap	Depreciation Depreciation	13285	USD
CY2016Q2	us-gaap	Depreciation Depreciation	20593	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.34
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.23
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.36
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.06
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.06
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	790487	USD
CY2016Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	330925	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P14M
CY2016Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1900000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2015Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	227206	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	1989162	USD
CY2016Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	445660	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	926671	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1087686	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	284005	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-43787	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2122847	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1049815	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2149647	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3154730	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4579576	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5329571	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10962916	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	130199	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-531531	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-554045	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-459562	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19266350	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2269398	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1641750	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	4133905	USD
CY2016Q2	us-gaap	Long Term Debt LongTermDebt	4680728	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14599627	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	542524	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6443	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4015	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	546823	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	403344	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-595679	USD
	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	0	USD
	us-gaap	Increase Decrease In Prepaid Supplies IncreaseDecreaseInPrepaidSupplies	293100	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	281996	USD
	us-gaap	Interest Expense InterestExpense	546823	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	0	USD
CY2015Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	5653	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	8910	USD
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	6397	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	8911	USD
CY2016Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	8554	USD
CY2015Q4	us-gaap	Liabilities Liabilities	8362078	USD
CY2016Q2	us-gaap	Liabilities Liabilities	7385813	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30082374	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6907527	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11194132	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-3154730	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4579576	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-5329571	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10962916	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	3387589	USD
	us-gaap	Operating Expenses OperatingExpenses	6488709	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	5483037	USD
	us-gaap	Operating Expenses OperatingExpenses	11320444	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3387589	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6488709	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5483037	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11320444	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	119756	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	68432	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	51324	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	50000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	54000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	797425	USD
CY2016Q2	us-gaap	Other Assets Current OtherAssetsCurrent	767020	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	148663	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6443	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.018
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4015	USD
CY2015Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	1115657	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	429964	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	480947	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	260000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.942
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.827
CY2016Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	1067731	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	14500000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	691187	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	372011	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	376026	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	180922	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	143974	USD
CY2016Q2	us-gaap	Rental Properties RentalProperties	8063	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2299903	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4365862	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4433222	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9170797	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-74137740	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85100656	USD
CY2015Q2	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
CY2016Q2	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.013
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	12000000	shares
CY2005Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	6000000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	57968	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1937750	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	51345	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10719904	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12599686	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.18
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.05
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8820320	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.22
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.45
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y7M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y8M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y7M18D
CY2016Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.33
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	642210	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	21720296	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	11880537	USD
CY2015Q4	us-gaap	Supplies Supplies	1158632	USD
CY2016Q2	us-gaap	Supplies Supplies	1661658	USD
CY2016Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	883062	USD
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3538739	USD
CY2015Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	4197375	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	597719	USD
CY2015Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2894871	USD
CY2015Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1958775	USD
CY2016Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1063335	USD
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90254823	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	84070845	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92878262	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92072062	shares
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassification</font><font style="font-family:inherit;font-size:10pt;"> - Certain prior year amounts included in the prior year consolidated financial statements have been reclassified to conform to the current year presentation.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates </font><font style="font-family:inherit;font-size:10pt;">– The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these consolidated financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-019182-index-headers.html	Edgar Link	pending
0001628280-16-019182-index.html	Edgar Link	pending
0001628280-16-019182.txt	Edgar Link	pending
0001628280-16-019182-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
imuc-20160630.xml	Edgar Link	completed
imuc-20160630.xsd	Edgar Link	pending
imuc-20160630_cal.xml	Edgar Link	unprocessable
imuc-20160630_def.xml	Edgar Link	unprocessable
imuc-20160630_lab.xml	Edgar Link	unprocessable
imuc-20160630_pre.xml	Edgar Link	unprocessable
imuc-63016x10q.htm	Edgar Link	pending
imuc-63016xexhibit101.htm	Edgar Link	pending
imuc-63016xexhibit311.htm	Edgar Link	pending
imuc-63016xexhibit312.htm	Edgar Link	pending
imuc-63016xexhibit321.htm	Edgar Link	pending
imuc-63016xexhibit322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc

2016 Q3 Form 10-Q Financial Statement

#000162828016019182 Filed on August 22, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUC EOM Pharmaceutical Holdings, Inc. Stock $imuc

2016 Q3 Form 10-Q Financial Statement

#000162828016019182 Filed on August 22, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUC
EOM Pharmaceutical Holdings, Inc. Stock $imuc